Why the study?
Diabetic retinopathy is a leading cause of blindness with complex pathophysiology, and angiopoietin signalling has recently emerged as a potential novel therapeutic target.
Angiopoietin signalling plays a key role in the pathophysiology of diabetic retinopathy and represents a potential novel therapeutic target.
Authors
No takes yet. Share an insight, caveat, or question.
Angiopoietin signalling may offer novel therapeutic targets in diabetic retinopathy; leaves open confirmation in prospective clinical trials.
Whitehead et al. (2019) studied this question.